Abstract Number: 1641 • ACR Convergence 2020
Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab: Results from a 56-Week Randomized NSAID-Controlled Study
Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…Abstract Number: 1657 • ACR Convergence 2020
Do Comorbidities Limit Improvement in Pain and Physical Function After Total Knee Arthroplasty in Patients with Knee Osteoarthritis?
Background/Purpose: Individuals with knee osteoarthritis (OA) are increasingly living with multiple comorbid conditions. The presence of comorbidities has been associated with having worse OA symptoms…Abstract Number: 0150 • ACR Convergence 2020
The Preparation Experience for Total Knee Arthroplasty of Patients with Osteoarthritis: A Cross-Sectional Survey
Background/Purpose: We previously identified several barriers and facilitators of exercise before total knee arthroplasty (TKA) in a small qualitative study, as well as the existence…Abstract Number: 0700 • ACR Convergence 2020
Lipoxin A4 Induces Lipid Class Switching and Inflammation Resolution at the Genomic Level in Human Osteoarthritis
Background/Purpose: Human OA-affected cartilage does not show the cardinal signs of inflammation (redness and swelling with heat and pain—rubor et tumor cum calore et dolor) because…Abstract Number: 1100 • ACR Convergence 2020
The Hand Osteoarthritis Registry of New York University: Impacts of Gender and Obesity
Background/Purpose: Hand osteoarthritis (HOA) data is often obtained from large knee OA cohorts. Targeted HOA cohorts in Europe have shed light on this disease, but…Abstract Number: 1116 • ACR Convergence 2020
Magnetic Resonance Imaging Structural Changes Correlated with Knee Extension: Data from the Osteoarthritis Initiative
Background/Purpose: Knee OA is often accompanied by loss of passive extension, termed a flexion contracture (FC), resulting in worse clinical outcomes. To our knowledge, MRI-based…Abstract Number: 1482 • ACR Convergence 2020
Joint Safety with Tanezumab: Integrated Analyses from Randomized Controlled Phase 3 Studies in Patients with Osteoarthritis
Background/Purpose: Tanezumab, a monoclonal antibody that inhibits nerve growth factor, has been shown effective in the management of osteoarthritis (OA) pain.1,2 Due to the potential…Abstract Number: 1642 • ACR Convergence 2020
Observed Efficacy with Subcutaneous Tanezumab Is Early and Maintained in Patients with Osteoarthritis: Results from a 56-Week Randomized NSAID-Controlled Study
Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…Abstract Number: 1658 • ACR Convergence 2020
Mediation of the Association Between Obesity and Osteoarthritis by Blood Pressure, Arterial Stiffness, and Subclinical Atherosclerosis
Background/Purpose: Obesity-related metabolic dysregulation may lead to atherosclerotic vascular changes. It has been hypothesized that a compromised blood flow may cause detrimental changes to the…Abstract Number: L05 • 2019 ACR/ARP Annual Meeting
Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA
Background/Purpose: A non-drug biomarker study showed senescent cell (SnC) burden in OA synovial tissue to correlate with disease severity, inflammation, and knee pain (C. Yohn,…Abstract Number: 1129 • 2019 ACR/ARP Annual Meeting
Direct Medical and Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States
Background/Purpose: Symptomatic knee OA affects 14 million adults in the US. Recent estimates suggest that about 40% of people with knee OA are taking prescription…Abstract Number: 1317 • 2019 ACR/ARP Annual Meeting
Frail Patients Have Worse Function After Total Knee Replacement
Background/Purpose: To determine whether frailty is associated with patient outcomes 1 year after total knee replacement (TKR).Methods: Patients ≥65yo scheduled for elective primary TKR for…Abstract Number: 1968 • 2019 ACR/ARP Annual Meeting
A Drug Repurposing Story: New Therapeutic Tools Ready to Block Innate Immune Responses in Osteoarthritis
Background/Purpose: Rheumatic diseases, also known as musculoskeletal pathologies, are steadily rising their prevalence. This worldwide phenomenon is depriving our society of their life quality and…Abstract Number: 2057 • 2019 ACR/ARP Annual Meeting
Cross-sectional Associations of Multiple Joint Osteoarthritis in the Osteoarthritis Initiative
Background/Purpose: Multiple joint osteoarthritis (MJOA) may represent a unique phenotype of osteoarthritis related to systemic factors associated with pathologic aging. We tested the hypothesis that metabolic…Abstract Number: 2189 • 2019 ACR/ARP Annual Meeting
Reference Curves for the Knee Injury and Osteoarthritis Outcome Score in the Middle-aged Dutch Population
Background/Purpose: The Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire is a widely used patient-reported outcome tool, developed to evaluate short- and long-term knee symptoms…
- « Previous Page
- 1
- …
- 45
- 46
- 47
- 48
- 49
- …
- 71
- Next Page »
